that is correct they are a small Israeli biotech and what you most likely saw was NIS sheckels
Their current cash is 18 million us dollars and once again they burn 1 million per month--simply go to the press release that they made 5 or 6 weeks ago for there qtrly earning --simple as that everything is right there.
Don't be so foolish as to think that the market is dumb and that today you discovered it
they burn around 1 million per qtr and have enough per the cfo to mid 2015--don't let these day traders spreading false info lure you in. I would not be buying today fyi..
You have many catalysts on this stock and some coming very soon. there Novel cancer drug 8040 should be releasing interim p2 results any day now. This will move the stock tremendously 50-100% up if positive imo. Also there hepatitis drug 8020 should be releasing p2 results soon also.
You also have the potential for several partnership announcements which could come at any time as they say they are in advance discussions with several company's.
So all in all if everything hits on all cylinders you could realistically get a 200%$ rise in a short period of time in my humble opinion. You have to decide on the risk/reward..
I agree 2014 looks promising But I am concerned about this minor delay. usually when the news is great they always get the info out ASAP But when bad they drag there feet and put it out late as possible-especially because they have there shareholder meeting I think next Monday for there pay raises etc., cant see any bad news being released before then? but good news yes they would. if this failed it would move down50% for sure if good up 50 I think. we will see-sorry bout your bad beat cgen-its a tough game to play boscolatush
i hope i'm wrong but I do not find it a good sign that they did not announce the results of 8040 at the ash conference.
The press release was complete garbage as this was not new news. they said a month or 2 ago that it would be announced at the ash so i'm amazed that it was not.
I never like when something is supposed to happen in a biotech and then there is a delay.
Aegis analyst Ram Selvaraju commented, “this new data significantly enhances the level of validation for BL-7040's mechanism of action in IBD. Biopsies were taken from patients before and after treatment and subjected to both histological and cytokine analysis in a blinded manner. Neutrophil levels were shown to be significantly reduced (p=0.002) in patients treated with BL-7040. Neutrophils are implicated in tissue damage in IBD, and their levels go down as disease severity decreases. In this respect, all patients whose neutrophil levels were reduced also showed a clinical improvement as assessed by their Mayo score, the gold standard for assessing ulcerative colitis therapy.”
Selvaraju continued that the market for BL-7040 is highly attractive, with over 2 million people being affected with IBD in several major markets. While sales in monitored markets were $7.2 billion last year, the analyst sees that growing to $8 billion or more by 2020. Of the expected total, about $6.5 billion will come from the U.S.
Additionally, Selvaraju sees “results from the Phase 1 trial of BL-8020 and the Phase 2 open-label trial of BL-8040 in the next 3-4 months, along with top-line Phase 3 data for BL-1040, a novel agent in the cardiology field, in 2014.”
Seems like over the next 6-12 months that their are many catalysts for this little gem of a company. Some of the catalysts are soon as they should be announcing the interim results for 8040 sometime soon and they will be presenting at the ASH conference in New Orleans I think between the 7th and 9th.
The hepatitis drug ph2 will be announced soon also from what they say. They have also stated that they are in advanced talks with several companys with several of their drug candidates.
The Investor day in New York seems to have been a big success. I read over the presentation and it looked really interesting .
All in all a very interesting company for such a small market cap imo..Big potential
Supposedly it was a full house and interest in the event was high. Big pipeline and on some unexpected day you can expect this to soar 100%...
Seems like there is no hype around the upcoming interim results announcement for 8040. I did not own BLRX until the summer but I went back and looked at the message board from prior to the schizophrenia drug release and it seemed like a ,lot of hype as the stock went up 100% prior to the announcement.
fast forward to now 0 hype and everyone is nervous judging by the trading-not much volume recently etc,. I wonder if the company will even give advance notice of a release date or just release the results? Seems like there is no set date
As far as there cash position don't forget that in q1 they are getting the results of there heart drug from Ikaria which would trigger I think around a 40 million dollar payment. Plus then you have possible deals like you said with 5010 and many of there other drug candidates.
I think it is highly unlikely that they will sell additional shares with so many big cash catalysts coming so soon--and I assume that in the next few weeks the interim results on the cancer drug. Unlike the schizophrenia drug there is no hype surrounding this which is good because if results are good the stock should shoot up 50%-100% imo as no one is expecting anything.
This seems like a great sign towards the significance of 8040 towards various blood cancer therapy's. Another good sign is that the Sloan Kettering doctor is speaking next week at the conference and I would imagine results are coming soon on this.
MD Anderson-Northwestern and Sloan Kettering 3 of the most respected cancer research facilities in the world are part of this 8040 which bodes well--would imagine several big pharmas are looking at BLRX....
This stock will be eventually priced correctly with a market cap of 600 million.
This is from the Q2 release so I would imagine that November is the month like yosef wrote-but you never know they could always surprise everyone with an early release
"We are also very pleased with the progress of the Phase 2 clinical trial for BL-8040, a best-in-class CXCR4 antagonist for the treatment of hematological cancers such as AML. We are on track to deliver partial results from the trial in the fourth quarter of 2013, with final results expected to be available by the second half of 2014."
of course it can not go up every single day and the big fish need an opportunity to get in so they shake out the week ones like us.
This stock is a winner imo and you should buy on days like this. Extremely undervalued and they just added a first of its kind diabetes drug to there already big portfolio..
I really believe that this stock is extremely undervalued and that it will rise over the next 6 months or so given that they have so many catalysts coming up that are pretty exciting.
But how many of us-myself included will be able to hang on for such a ride? Stocks like acadia-pcyc etc all had big bump ups followed by pullbacks and on each occasion it would have been easy to sell with a 50% profit and on each pullback it is easy to get scared and sell.
Especially hard to hold when you see the big fish selling after a big run up-but they too miss the big run ups and are crying when a stock that they once owned goes thru the roof-nothing worse than having owned a stock and seeing it go thru the roof AFTER you sold.
I just started buying in july so my average is low enough, but I am adding on these pullbacks. We never know on which day it could shoot up 100% but it will be unexpected I think.
I found that report after googling it-it was from last oct when the price was 2.55-nice info on the write up.
A Capital-Efficient Drug Development Machine
■ Initiating Coverage. We are initiating coverage of BioLineRx, Ltd.,
an Israel-based development-stage biopharmaceutical firm, with a Buy
rating and an 18-month price target of $11.00 per share. In our view,
this company is one of the most risk-mitigated, undervalued entities
in the biotechnology sector. The firm possesses a broad pipeline of
clinical as well as preclinical candidates and is slated to report critical
clinical data on two of its most advanced programs in 2013. With
an enterprise value of roughly $10mm, we believe that BioLineRx
provides a unique arbitrage opportunity for the development-stage
■ Cost-Effective Business Model. In our view, BioLineRx has built
one of the industry's deepest pipelines while keeping its expenditures
on in-licensing compounds low. We also note that the firm typically
conducts relatively short-term clinical trials, enabling results to be
obtained rapidly and decisions made quickly regarding which drug
candidates are to be advanced. The firm has burned just over $100mm
since inception and has two candidates in Phase 3 trials currently,
with several others having completed proof-of-concept efficacy trials
in human patients.
■ Proven Drug Development / Partnering Expertise. In our view,
investors should have confidence in BioLineRx management's
capabilities with respect to executing on the implementation of
the firm's "identify-develop-partner" business model. The firm has
thus far inked two partnerships on its most advanced candidates -
the partnership with Cypress Bioscience on BL-1020, the atypical
antipsychotic agent, and the licensing agreement with Ikaria on
BL-1040, BioLineRx's proprietary bioresorbable cardiac matrix. The
upfront payments in these deals ($37mm) were equivalent to the
company's current market cap.
■ Multiple Shots On Goal. One of BioLineRx's most substantial
selling points, in our opinion, is the fact that the firm has such an
extensive pipeline. It crosses the boundaries of therapeutic areas and
opportunistically pursues pipeline expansion possibilities. The firm's
extensive clinical pipeline alone contains 6 or 7 candidates that have
all established safety and tolerability in human subjects. The company
has selected over 25 candidates to work on thus far since inception in
Don't lose sight of the fact that this company has moved up from 1.55 in a short time. With around 6 drugs in clinical and around 10 or so pre clinical and a massive 20 plus in the incubator in my opinion this company will soar over the next few months with trial results or partnerships. Who knows-but it will be unexpected and usually just when you sell your shares.
I used to own HGSI and it went from 7- to 12 and I sold baught back again at 7.5 and sold at 8 bucks because it looked like the big fish were selling only to see it up 100% a few weeks later with me not in it-lesson learned-if you own a good one stick with it even thru the volatility because on any given day something great can happen and it is a nightmare if you sold out....
I am of the opinion that this diamond sporting a 68 million dollar market cap will get a buyout offer in the 180-200 million plus range.
With such an extensive and deep pipeline of 6 or 7 clinical and a massive 10 or so pre clinical not to mention probably 20 or so incubator candidates with bioline jersusalem certainly a large or medium pharma would want this company for there pipeline and technical expertise.
I have searched high and low for a company in the 500 million and even 1 billion market cap and have not come up with one company that has the extensive pipeline of this Biotech pioneer.
Certainly we know that they are talking with other companys about partnerships as they have said so. And with the new board member Dr. Borman the handwriting is on the wall. With the exciting new cancer drug-hepatitis drugs-celiac etc the stock price could quickly surge thru 10 dollars in my opinion.
In my opinion Bioline rx is set to soar-any positive announcements sends this up 100% or more in just 1 session.......